Comprehensive Genomic Insight for Precision Medicine
The IVDNGS™ Whole Exome Sequencing Panel offers a powerful, high-throughput solution for analyzing the protein-coding regions (exons) of over 20,000 genes. This NGS-based assay is designed to uncover pathogenic variants responsible for rare genetic disorders, complex diseases, undiagnosed conditions, and inherited syndromes.
By focusing on the exome—which contains approximately 85% of disease-causing mutations—the WES panel provides a cost-effective and clinically actionable alternative to whole genome sequencing.
Targets >20,000 genes representing the entire human exome
Detects SNVs, indels, and splice-site variants
Suitable for a wide range of indications: neurology, oncology, metabolic, and rare diseases
Provides diagnostic clarity in complex, undiagnosed clinical cases
Integrates with clinical phenotype interpretation tools
Complies with ISO 13485 and IVD-grade quality standards
Available for trio testing (proband + parents) for inheritance analysis
| Parameter | Details |
|---|---|
| Test Name | IVDNGS™ Whole Exome Sequencing (WES) Panel |
| Technology | Targeted Next-Generation Sequencing (NGS) |
| Genes Covered | >20,000 protein-coding genes |
| Variants Detected | SNVs, Indels, Splice-site mutations |
| Sample Type | Whole blood, saliva, or buccal swab |
| Turnaround Time | 15–21 working days |
| Applications | Rare disease diagnostics, inherited syndromes, clinical phenotype correlation |
| Regulatory Compliance | ISO 13485, IVD-grade |
Copyright © 2025 https://probgenbiotech.com/ All Rights Reserved.